Engineered antibodies that stabilize drug-modified KRASG12C neoantigens enable selective and potent cross-HLA immunotherapy
- Lorenzo Maso
- Sarah A. Mosure
- Sergio A. Rodriguez-Aponte
- Angelina Pizzo
- Diamond N. Mensah
- Matthew Southard
- Samantha Sze
- Tanvir Ahmed
- Brian Vash
- Takamitsu Hattori
- Epsa Rajak
- Akiko Koide
- Benjamin G. Neel
- Shohei Koide
- Weifeng Liu
- Sean T. Toenjes
- Paul Da Silva Jardine
- Rajesh Chopra
- Christoph Rader
- Lauren E. Stopfer
2025-12-17